Kriya Appoints Pedro Huertas M.D., Ph.D., as Chief Medical Officer of its Rare Disease Division

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Kriya Therapeutics, Inc. , a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, announced today that it has appointed Pedro Huertas, M.D., Ph.D., as Chief Medical Officer of its Rare Disease Division.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, August 17, 2022
Information
Tags: 
Infectious Diseases, Hospitals, Genetics, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Multimedia, Ecosystem, Triangle Park (Quezon City), Silicon, Patient, Therapy, Degenerative disease, Twitter, Enzyme replacement therapy, Fabry disease, Ophthalmology, Conditional sentence, Genzyme, LinkedIn, Entrepreneurship, Disease, Pharmaceutical industry, Alpha-galactosidase, Kriyā, Pfizer
Geotags: 
CALIFORNIA, NORTH CAROLINA, UNITED STATES, NORTH AMERICA, EUROPE, JAPAN
⚠ generated by AI ↴
Organisation: 
KRIYA
Summary
Key Points: 
  • Kriya Therapeutics, Inc. , a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, announced today that it has appointed Pedro Huertas, M.D., Ph.D., as Chief Medical Officer of its Rare Disease Division.
  • In his role, Dr. Huertas will be responsible for the direction and execution of the companys clinical, medical and scientific plans to advance its rare disease pipeline.
  • Prior to joining Kriya, Dr. Huertas served as Chief Medical Officer at Inozyme Pharma, Sentien Biotechnologies, and Eloxx Pharmaceuticals.
  • Earlier in his career, Dr. Huertas also held clinical and development roles at Pfizer, Shire, Amicus, and Genzyme Corp.
    Pedro brings a wealth of experience to Kriya as we continue to advance our rare disease gene therapy portfolio, said Shankar Ramaswamy, M.D., Co-Founder and Chief Executive Officer of Kriya.


Kriya Therapeutics, Inc., a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, announced today that it has appointed Pedro Huertas, M.D., Ph.D., as Chief Medical Officer of its Rare Disease Division. In his role, Dr. Huertas will be responsible for the direction and execution of the company’s clinical, medical and scientific plans to advance its rare disease pipeline.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005231/en/

Pedro Huertas, M.D., Ph.D. (Photo: Business Wire)

Pedro Huertas, M.D., Ph.D. (Photo: Business Wire)

Dr. Huertas brings to Kriya three decades of experience advancing therapies for rare conditions across a spectrum of roles, including in preclinical and clinical research, clinical development, post-marketing development, and regulatory strategy. Prior to joining Kriya, Dr. Huertas served as Chief Medical Officer at Inozyme Pharma, Sentien Biotechnologies, and Eloxx Pharmaceuticals. Earlier in his career, Dr. Huertas also held clinical and development roles at Pfizer, Shire, Amicus, and Genzyme Corp.

“Pedro brings a wealth of experience to Kriya as we continue to advance our rare disease gene therapy portfolio,” said Shankar Ramaswamy, M.D., Co-Founder and Chief Executive Officer of Kriya. “His track record of success in developing impactful medicines has earned him the respect of the rare disease community – and we look forward to supporting him within our unique ecosystem to deliver transformative gene therapies to patients.”

Dr. Huertas’ extensive experience working with regulatory agencies around the world will further bolster Kriya’s mission to advance gene therapies to patients. While at Genzyme, he helped lead the successful effort to file for approval of Fabrazyme (agalsidase beta), an enzyme replacement therapy for Fabry disease, in the United States, Europe, and Japan.

“I’m excited to join a company with the potential to deliver several innovative, life-changing therapies to patients with rare diseases,” said Dr. Huertas. “Kriya’s fully integrated technology platform, advanced manufacturing capabilities and accomplished team offer significant advantages as it pursues its mission – and I am eager to deploy these capabilities to accelerate the delivery of gene therapies to patients who need them.”

About Kriya

Kriya is a fully integrated company pioneering novel technologies and therapeutics in gene therapy. The company aims to revolutionize how gene therapies are designed, developed, and manufactured, improving speed to market and delivering significant reductions in cost. The company is advancing a deep and diversified pipeline of innovative gene therapies in multiple therapeutic area divisions, with current pipeline programs in ophthalmology, oncology, rare disease and chronic disease. Kriya is backed by leading life sciences and technology investors, and has core operations in Silicon Valley, California and Research Triangle Park, North Carolina. For more information, please visit www.kriyatx.com and follow on LinkedIn and Twitter.

Copyright: 
Copyright Business Wire 2022